WBI Investments LLC bought a new stake in shares of The Clorox Company (NYSE:CLX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,965 shares of the company's stock, valued at approximately $806,000.
Several other large investors have also bought and sold shares of CLX. Brooklyn Investment Group increased its holdings in shares of Clorox by 163.8% in the fourth quarter. Brooklyn Investment Group now owns 153 shares of the company's stock valued at $25,000 after buying an additional 95 shares in the last quarter. Redwood Park Advisors LLC bought a new stake in shares of Clorox during the 4th quarter worth $26,000. Millstone Evans Group LLC acquired a new position in shares of Clorox in the 4th quarter worth $31,000. Asset Planning Inc acquired a new stake in shares of Clorox during the fourth quarter worth $32,000. Finally, GKV Capital Management Co. Inc. purchased a new stake in shares of Clorox during the fourth quarter valued at $32,000. Institutional investors own 78.53% of the company's stock.
Clorox Stock Up 0.0%
CLX stock traded up $0.07 during midday trading on Friday, reaching $130.97. The company had a trading volume of 1,243,078 shares, compared to its average volume of 1,331,005. The company has a 50 day moving average of $139.91 and a two-hundred day moving average of $152.60. The company has a market capitalization of $16.14 billion, a P/E ratio of 35.78, a PEG ratio of 2.62 and a beta of 0.60. The Clorox Company has a 1 year low of $127.60 and a 1 year high of $171.37. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52.
Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. During the same period last year, the company posted $1.71 earnings per share. The company's revenue was down 8.0% compared to the same quarter last year. On average, equities research analysts expect that The Clorox Company will post 7.15 earnings per share for the current fiscal year.
Clorox Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, May 9th. Shareholders of record on Wednesday, April 23rd were given a $1.22 dividend. This represents a $4.88 annualized dividend and a yield of 3.73%. The ex-dividend date was Wednesday, April 23rd. Clorox's payout ratio is currently 87.61%.
Analyst Upgrades and Downgrades
CLX has been the topic of a number of analyst reports. Citigroup dropped their price target on Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a research note on Monday, April 14th. Wells Fargo & Company decreased their target price on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. UBS Group cut their price target on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Evercore ISI set a $140.00 price target on shares of Clorox and gave the company an "underperform" rating in a research report on Tuesday, May 6th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $150.00 price objective on shares of Clorox in a research note on Thursday, January 30th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $151.23.
View Our Latest Research Report on Clorox
Insider Transactions at Clorox
In other news, Director Pierre R. Breber acquired 4,000 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director now owns 4,000 shares of the company's stock, valued at approximately $546,280. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.57% of the company's stock.
Clorox Company Profile
(
Free Report)
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
See Also
Before you consider Clorox, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.
While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
